UK consensus recommendations on the management of oral epithelial dysplasia during COVID-19 pandemic outbreaks.

COVID-19 Consensus guidelines Oral cancer prevention Oral epithelial dysplasia Potentially-malignant oral disorder SARS-CoV-2

Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
01 2021
Historique:
received: 29 09 2020
revised: 10 11 2020
accepted: 13 11 2020
pubmed: 25 11 2020
medline: 13 1 2021
entrez: 24 11 2020
Statut: ppublish

Résumé

Oral Epithelial Dysplasia (OED) is associated with an increased risk of oral cancer development. The SARS-CoV-2 pandemic is necessitating the suspension or dramatic reduction of face-to-face non-urgent elective services, including OED clinics. Little is known regarding the potential impact of elective services suspension upon the risk of OED progression, and whether alternative strategies (e.g. remote consultations) may be introduced to ensure OED surveillance. The aim of this paper is to provide expert-opinion consensus recommendations for the management of OED during the current and future pandemic outbreaks. A working group of nine UK-based senior clinicians and academics in Oral and Maxillofacial Surgery and Oral Medicine was created and twelve consensus statements were developed using a modified-Delphi process. Greater than 80% agreement was considered a consensus. Consensus was achieved for all twelve statements (89-100% agreement). The group agreed that, during the temporary suspension of elective services associated with COVID-19 pandemic outbreaks, patients with OED can be risk stratified to determine the length of accepted delay in face-to-face consultation. Remote consultations with patient-provided clinical photographs may be a useful way of maintaining a level of surveillance in this group of patients. Using an expert working group methodology, we have developed consensus recommendations for the monitoring of individuals with OED during pandemic outbreaks associated with temporary suspension of elective services. This has identified areas of future research and highlighted the need for a stronger evidence base to inform the set-up and delivery of surveillance regimens for patients with OED.

Identifiants

pubmed: 33232878
pii: S1368-8375(20)30546-7
doi: 10.1016/j.oraloncology.2020.105110
pmc: PMC7674996
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105110

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

J Am Dent Assoc. 2016 Oct;147(10):782-791.e1
pubmed: 27206728
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Mar;117(3):343-52
pubmed: 24388536
J Oral Pathol Med. 2011 Oct;40(9):677-83
pubmed: 21762430
Lancet Oncol. 2020 Jul;21(7):e350-e359
pubmed: 32534633
Clin Cancer Res. 2000 May;6(5):1702-10
pubmed: 10815888
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):612-627
pubmed: 29396319
Int J Gynecol Cancer. 2020 Aug;30(8):1097-1100
pubmed: 32487685
Tumori. 1986 Jun 30;72(3):307-12
pubmed: 3739009
Clin Infect Dis. 2021 Dec 6;73(11):e4047-e4057
pubmed: 32766823
Head Neck Pathol. 2007 Sep;1(1):61-6
pubmed: 20614284
Oral Oncol. 2012 Oct;48(10):969-976
pubmed: 22579265
J Infect. 2020 Aug;81(2):282-288
pubmed: 32479771
Oral Oncol. 2015 Oct;51(10):883-7
pubmed: 26198978
J Oral Pathol Med. 2008 Jan;37(1):1-10
pubmed: 18154571
BMJ. 2020 Jun 12;369:m2386
pubmed: 32532710
J Natl Cancer Inst. 2020 Oct 1;112(10):1047-1054
pubmed: 31860085
JAMA Dermatol. 2016 Jan;152(1):95-7
pubmed: 26443967
Lancet Oncol. 2020 Aug;21(8):1035-1044
pubmed: 32702311
Endoscopy. 2020 Oct;52(10):891-898
pubmed: 32643767
Cancer Prev Res (Phila). 2012 Sep;5(9):1081-9
pubmed: 22911111
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Br J Oral Maxillofac Surg. 2013 Oct;51(7):594-9
pubmed: 23601832
Head Neck. 2009 Dec;31(12):1600-9
pubmed: 19455705
J Oral Pathol Med. 2009 Jul;38(6):540-4
pubmed: 19453839
Head Neck. 2020 Mar;42(3):539-555
pubmed: 31803979
Oral Oncol. 2018 Mar;78:119-125
pubmed: 29496039
Cancer. 2021 Jul 15;127(14):2476-2488
pubmed: 33345297
Nat Cancer. 2020 Jun;1(6):565-567
pubmed: 35121972

Auteurs

Caroline Elizabeth McCarthy (CE)

Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Roy Castle Building, 200 London Road, Liverpool L3 9TA, UK. Electronic address: carolmc2@liverpool.ac.uk.

Stefano Fedele (S)

University College London, UCL Eastman Dental Institute, 256 Gray's Inn Road, London WC1X 8LD, UK; NIHR UCLH Biomedical Research Centre, Maple House Suite A 1st Floor, 149 Tottenham Court Road, London W1T 7DN, UK.

Michael Ho (M)

Leeds Teaching Hospitals NHS Trust, Clarendon Way, LS2 9LU Leeds, UK.

Richard Shaw (R)

Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Roy Castle Building, 200 London Road, Liverpool L3 9TA, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH